MUSK and thymoma: Fifty-two (64%) had very late-onset MG; 35% had a thymoma, and 72% had at least one comorbidity; seventy patients (86%) had antibodies against AChR, 7 (9%) against MuSK and 4 (5%) were seronegative (Fig. 2B).